NHSA (prev. SMIA)

Explore the landscape of NHSA (prev. SMIA) in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on NHSA (prev.  SMIA) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML
CompanyDrug

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

InnoCare Pharma (HKG: 9969; SHA: 688428) announced today that the first patient has been dosed in the registrational Phase III head‑to‑head clinical trial of the Company's novel BCL2 inhibitor mesutoclax…

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer's Disease Diagnosis and Treatment

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor
CompanyDrug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Policy / Regulatory

China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway

Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Policy / Regulatory

NHSA Targets NRDL Fund Supervision in 2026 Crackdown

CompanyDrug

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Policy / Regulatory

China Expands Medical Insurance Personal Account Pooling Nationwide

Show More